Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Gets Delisting Notice from NYSE AMEX

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic-test maker Interleukin Genetics said after the close of the market Friday that it has received a delisting notice from the New York Stock Exchange's American Stock Exchange.

The firm said that the exchange has initiated delist proceedings because it has not regained compliance with certain regulations — it has stockholders' equity of less than $6 million and losses from continuing operations and/or net losses in its five most recent fiscal years.

Interleukin received an initial letter of non-compliance from the exchange in December 2008. This past March, it said that the NYSE had granted the firm an extension to meet the exchange's continued listing standards.

Interleukin said that it will request a hearing with the exchange's Listing Qualifications Panel to appeal the decision. The request will stay delisting of the firm's stock until the panel issues a decision after the hearing.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.